摘要
目的:评价痰热清注射液联合西药治疗耐药菌肺部感染的临床疗效及安全性。方法:通过检索国家知识基础设施数据库(CNKI)、中国学术期刊数据库(CSPD)、中文科技期刊数据库(CCD)、中国生物医学文献数据库(CBM)、Pubmed、Embase及Cochrane Library数据库,搜集有关痰热清注射液治疗耐药菌感染的随机对照试验,并采用StataSE软件进行Meta分析。结果:痰热清注射液联合西药治疗耐药菌肺部感染能提高临床总有效率(RR=1.223,95%CI为1.138~1.314,P=0.000),提高临床治愈例数(MD=5.215,95%CI为2.347~8.878,P=0.000),及减少临床治愈时间(MD=-1.948,95%CI为-2.850~-1.046,P=0.009),差异均有统计学意义。结论:痰热清注射液治疗耐药菌肺部感染有较好的疗效和安全性。
Objective:To evaluate the clinical efficacy and safety of Tanreqing Injection combined with western medicine in the treatment of drug-resistant pulmonary infection.Methods:CNKI,CSPD,CCD,CBM,PubMed,Embase,and Cochrane Library were searched for the randomized controlled trials(RCTs)of Tanreqing Injection in the treatment of drug-resistant infections.Meta-analysis was carried out by using StataSE.Results:Tanreqing Injection combined with western medicine in the treatment of drug-resistant pulmonary infection could improve the total clinical effective rate[RR=1.223,95%CI(1.138 to 1.314),P=0.000],increase the number of cured cases[MD=5.215,95%CI(2.347 to 8.878),P=0.000],and shorten the clinical treatment time[MD=-1.948,95%CI(-2.850 to-1.046),P=0.009].Conclusion:Tanreqing Injection possesses good efficacy and safety in the treatment of drug-resistant pulmonary infection.
作者
李芷悦
李宗芳
任培中
陈秋仪
崔红生
LI Zhiyue;LI Zongfang;REN Peizhong;CHEN Qiuyi;CUI Hongsheng(Pneumology Department,Beijing University of Chinese Medicine Third Affiliated Hospital,Beijing 100029,China;Pneumology Department,Rizhao Hospital of Traditional Chinese Medicine,Rizhao 276800,China)
出处
《世界中医药》
CAS
2022年第7期993-997,共5页
World Chinese Medicine
基金
山东省中医药科技发展计划项目(2019-0803)。
关键词
痰热清注射液
耐药菌肺部感染
Meta分析
随机对照试验
系统评价
临床疗效
鲍曼不动杆菌
铜绿假单胞菌
金黄色葡萄球菌
Tanreqing Injection
Drug-resistant pulmonary infection
Meta-analysis
Randomized controlled trial
Systematic review
Clinical efficacy
Acinetobacter baumannii
Pseudomonas aeruginosa
Staphylococcus aureus
